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Abstract
Background: Multi-assay algorithms (MAAs) can be used to estimate HIV incidence in cross-sectional surveys. We compared
the performance of two MAAs that use HIV diversity as one of four biomarkers for analysis of HIV incidence.
Methods: Both MAAs included two serologic assays (LAg-Avidity assay and BioRad-Avidity assay), HIV viral load, and an HIV
diversity assay. HIV diversity was quantified using either a high resolution melting (HRM) diversity assay that does not
require HIV sequencing (HRM score for a 239 base pair env region) or sequence ambiguity (the percentage of ambiguous
bases in a 1,302 base pair pol region). Samples were classified as MAA positive (likely from individuals with recent HIV
infection) if they met the criteria for all of the assays in the MAA. The following performance characteristics were assessed:
(1) the proportion of samples classified as MAA positive as a function of duration of infection, (2) the mean window period,
(3) the shadow (the time period before sample collection that is being assessed by the MAA), and (4) the accuracy of cross-
sectional incidence estimates for three cohort studies.
Results: The proportion of samples classified as MAA positive as a function of duration of infection was nearly identical for
the two MAAs. The mean window period was 141 days for the HRM-based MAA and 131 days for the sequence ambiguity-
based MAA. The shadows for both MAAs were ,1 year. Both MAAs provided cross-sectional HIV incidence estimates that
were very similar to longitudinal incidence estimates based on HIV seroconversion.
Conclusions: MAAs that include the LAg-Avidity assay, the BioRad-Avidity assay, HIV viral load, and HIV diversity can provide
accurate HIV incidence estimates. Sequence ambiguity measures obtained using a commercially-available HIV genotyping
system can be used as an alternative to HRM scores in MAAs for cross-sectional HIV incidence estimation.
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HIV incidence is the rate of new HIV infections in a population.
Reliable incidence estimates are needed to monitor and respond to
the HIV/AIDS epidemic. Longitudinal cohort studies and cross-
sectional surveys have been used to estimate HIV incidence.
Cross-sectional incidence estimation may be preferred in some
settings [1].
Serologic assays have been developed for cross-sectional HIV
incidence estimation. However, these assays can overestimate
incidence because some individuals with long-term HIV infection
are misclassified as assay positive [2]. Some investigators have
suggested using sequence-based measures of HIV diversity for
HIV incidence estimation (e.g., by quantifying the proportion of
ambiguous or mixed base positions in Sanger sequencing data or
by using computational methods to quantify HIV diversity using
next generation sequencing data) [3,4,5,6]. This approach is based
on the premise that HIV diversity tends to increase over time
following HIV infection [7,8]. Potential limitations of using
sequence-based diversity data alone for HIV incidence estimation
have been noted [5]. The cost of this approach would also be
prohibitive for large cross-sectional surveys.
Multi-assay algorithms (MAAs) have recently been developed
that provide accurate cross-sectional HIV incidence estimates for
populations in the United States (US), where most HIV infections
are subtype B [9]. These MAAs include both serologic assays and
non-serologic biomarkers, such as CD4 cell count and HIV viral
load [2,9,10]. We recently developed a robust MAA that includes
the BED capture enzyme immunoassay (BED-CEIA, Calypte
Biomedical Corporation, Lake Oswego, OR, USA [11]), an
avidity assay based on the Genetic Systems 1/2+O EIA (BioRad-
Avidity assay; BioRad Laboratories, Redmond, WA, USA, [12]),
HIV viral load, and HIV diversity [13]. An advantage of this
MAA is that it does not require CD4 cell enumeration at the time
of sample collection [13]. In this MAA, HIV diversity in the env
region is quantified using a high resolution melting (HRM)
diversity assay that does not require sequencing [14,15]. The assay
is less expensive and easier to perform than sequencing assays and
simplifies data analysis, since the output of the HRM diversity
assay is a single numeric HRM score. The HRM diversity assay
has been validated by comparison of HRM scores to diversity
measures obtained from next generation sequencing data [15]. In
previous reports, this assay has been used to compare HIV
diversity in individuals with recent vs. non-recent infection [8] and
to analyze HIV diversification over time [15,16]. The assay has
also been used in studies that demonstrate the biological relevance
of HRM-derived measures, including the association of HRM
scores with infant survival [17] and response to antiretroviral
treatment [18].
While the HRM diversity assay offers many advantages for
measuring HIV diversity, it is not widely available. For this reason,
we also evaluated the performance of a MAA that includes
sequence ambiguity in the pol region as a measure of HIV
diversity. Previous studies have used pol region sequence ambiguity
to measure HIV diversity for HIV incidence analysis [3,5,19]. In
this report, sequence ambiguity was quantified by measuring the
percentage of ambiguous bases in pol region consensus sequences
generated using an HIV genotyping system developed for HIV
drug resistance testing (ViroSeq HIV-1 Genotyping System,
Celera, Alameda, CA, USA). While this approach is more labor-
intensive and costly than measuring HIV diversity using the HRM
diversity assay, the ViroSeq system is commercially available and
is used in a large number of laboratories in the US and elsewhere.
The two MAAs evaluated in this report include a limiting
antigen avidity assay recently developed by the US Centers for
Disease Control for HIV incidence estimation (LAg-Avidity assay,
Sedia Biosciences Corporation, Portland, OR, USA [20]) rather
than the BED-CEIA. The LAg-Avidity assay is combined with a
second serologic assay, the BioRad-Avidity assay (described
above), as well as two non-serologic biomarkers: HIV viral load
and HIV diversity (HRM score for a region in HIV env or the level
of sequence ambiguity in pol region data from population
sequencing). Samples were considered to be MAA positive (likely
from individuals with recent HIV infection) if they met the criteria
for all of the assays in the MAA.
The performance of the two MAAs was assessed using a large
set of samples from individuals in three clinical cohorts with known
duration of HIV infection. Performance was assessed by evaluat-
ing: (1) the proportion of samples classified as MAA positive as a
function of duration of infection, (2) the mean window period (the
mean duration of time that individuals were MAA positive), (3) the
shadow (the time period prior to sample collection that is being
assessed by the MAA [2,21]), and (4) the accuracy of MAA-derived
cross-sectional incidence estimates for three cohort studies. The
performance of these two MAAs was also compared to the
performance of an optimized 2-assay MAA that does not include a
diversity measure.
Methods
Ethics Statement
The Multicenter AIDS Cohort Study (MACS), AIDS Linked to
the IntraVenous Experience (ALIVE), HIV Network for Preven-
tion Trials (HIVNET) 001/001.1, Johns Hopkins Hospital
Clinical Cohort (JHHCC), HIV Prevention Trials Network
(HPTN) 061, and HPTN 064 studies were conducted according
to the ethical standards set forth by the institutional review boards
of the participating institutions and the Helsinki Declaration of the
World Medical Association; participants provided written in-
formed consent. The work reported here included analysis of
stored samples and data from those studies; this work was
approved by Institutional Review Boards at the participating
institutions. No participants were recruited or followed during the
course of this work.
Samples used for MAA development
Stored plasma and serum samples collected 1 month to .8
years after seroconversion were acquired from cohort studies in
the US (1,782 samples from 709 individuals, see Table S1). The
sources of these samples were: the MACS [22] (men who have sex
with men [MSM], 564 samples from 365 individuals), the ALIVE
cohort [23] (persons who inject drugs, 410 samples from 241
individuals), and the HIVNET 001/001.1 vaccine preparedness
cohort [24] (men and women with different risk factors for HIV
acquisition, 808 samples from 103 individuals). Five hundred
additional samples from the JHHCC that were collected .8 years
after seroconversion were also analyzed [25]; approximately half
of the JHHCC study participants are persons who inject drugs.
Detailed descriptions of these sample sets and the methods used to
estimate the seroconversion date for each sample were reported
previously [9,26].
Samples used for cross-sectional incidence estimation
Stored plasma and serum samples used for cross-sectional
incidence estimation were obtained from three cohort studies in
the US: (1) the HPTN 064 cohort (low incidence) [27], (2) the
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HPTN 061 cohort (high incidence) [28]. These samples were
collected at follow-up visits 6–18 months after study enrollment
(see Table S1).
Laboratory methods
Testing with the LAg-Avidity and BioRad-Avidity assays was
performed previously [9,10]. LAg-Avidity assay results are
reported as normalized optical density units (OD-n). BioRad-
Avidity assay results are reported as avidity index (%). Samples
that had a LAg-Avidity result ,2.9 OD-n and a BioRad-Avidity
avidity index result ,85% (N=213) were tested with an HIV viral
load assay. One hundred nineteen of those samples analyzed had a
viral load .400 copies/mL, and 113 (95.0%) of the 119 samples
were available for evaluation with the HRM diversity assay and
ViroSeq system (the remaining six samples were depleted in prior
testing). HRM scores were obtained for 111 (98.2%) of the 113
samples (1 from the MACS cohort, 7 from the ALIVE cohort, and
103 from the HIVNET 001/001.1 cohort; 2 samples failed
analysis). Sequence ambiguity measures were obtained for 108
(95.6%) of the 113 samples (1 from the MACS cohort, 7 from the
ALIVE cohort, and 100 from the HIVNET 001/001.1 cohort; 5
samples failed analysis).
The HRM diversity assay was performed as previously
described [8,14]. Briefly, a region of HIV env was amplified. A
smaller env region (ENV1, 239 base pairs) was then amplified in a
nested polymerase chain reaction (PCR) that included a fluores-
cent, duplex-dependent DNA dye (LCGreen Plus, BioFire
Diagnostics, Inc., Salt Lake City, UT, USA). After the nested
PCR step, the samples were analyzed using a LightScanner
instrument (BioFire Diagnostics, Inc.); in this step, samples were
warmed, and the fluorescent dye was released as the DNA
duplexes melted. The negative derivative of fluorescence vs.
temperature (–dF/dT) was plotted against temperature to yield the
melting peak for each sample. The width of the melting peak
(which corresponds to the level of genetic diversity in the
amplicon) was reported as the ENV1 HRM score. HRM scores
were determined using the DivMelt software package (DivMelt,
ENV1 protocol) [29].
The ViroSeq HIV-1 Genotyping System was used to generate
HIV pol sequence data using 6–7 primers and to manually edit
assembled sequences to yield a single consensus sequence (1,302
base pairs). Mixed base positions were identified according to the
manufacturer’s instructions. The final consensus sequence was
exported in FASTA format. A Perl script was used to calculate the
number of mixed base positions in each sequence and to
determine the percentage of bases in each sequence that were
ambiguous: sequence ambiguity (%)=[(number of mixed base
positions)6(100)]/(total number of positions). FASTA sequence
data were submitted to GenBank (National Center for Biotech-
nology Information, U.S. National Library of Medicine, Bethesda,
MD, USA) and were assigned accession numbers KF729799-
KF729936.
Statistical methods
Samples were classified as MAA positive if they met the criteria
for all component assays. Samples were classified as MAA negative
if they failed to meet the criteria for one or more of the component
assays. MAAs were evaluated using statistical methods described
previously [2,26]. For each MAA, the mean window period and
shadow were calculated by fitting cubic splines to the data;
confidence intervals were determined using blocked bootstrapping.
The results were used to generate probability curves that show the
proportion of MAA positive samples as a function of time since
HIV seroconversion. The mean window period corresponds to the
area under the probability curve [26]. As noted above, the shadow
measures the time period prior to sample collection that is being
assessed by the MAA. One can also think of the shadow as follows:
among persons who are MAA positive (in the window period) at
the time of the survey, the shadow represents the average duration
of time that those persons already spent in the window period
prior to the survey. Additional information about the methods
used to calculate the mean window period and shadow is provided
in a previous report [26].
Samples that were missing HRM diversity assay or sequence
ambiguity results (sample not available or assay failure) were
excluded from the analysis. The potential impact of these missing
values was assessed using a secondary analysis that incorporated
the partial information available for these samples (i.e., data from
the serologic and viral load assays); this analysis assumed that
samples missing diversity data and samples with diversity data
were not systematically different with regard to the relationship
between being MAA positive and the duration of infection.
Incidence estimation
Incidence estimates for the HPTN 064, HIVNET 001/001.1,
and HPTN 061 cohorts were calculated using the following
formula: Incidence=[(# MAA positive samples)6(100)]/[(num-
ber uninfected individuals)6(mean window period)] [13]. Confi-
dence intervals were calculated as previously described [13,30].
Incidence estimates were evaluated by calculating the percent
difference between the incidence estimate obtained using a MAA
and the incidence estimate obtained from longitudinal cohort
follow-up, where % difference=[(the absolute value of the MAA-
based incidence estimate minus the longitudinal incidence
estimate)6(100)]/(the longitudinal incidence estimate). Statistical
analyses were performed using the R statistical programming
language [31] or Mathematica (Wolfram Research, Champaign,
IL, USA).
Results
We evaluated two new 4-assay MAAs that include the BioRad-
Avidity assay, the LAg-Avidity assay, HIV viral load, and HIV
diversity (measured using the HRM diversity assay or sequence
ambiguity, Figure 1). Both MAAs used the following assay cutoffs:
BioRad-Avidity assay ,85%, LAg-Avidity assay ,2.9 OD-n, and
HIV viral load .400 copies/mL. The cutoffs for these three assays
are the same as those in an optimized 4-assay MAA that also
includes CD4 cell count [10]; that MAA was identified by
comparing .500,000 candidate MAAs that included different
assays and assay cutoffs [10]. The two new MAAs described in this
report replace CD4 cell count in the optimized MAA with a
diversity measure. One of the two new MAAs described in this
report includes the HRM diversity assay for the ENV1 region as
the fourth assay, using an HRM score cutoff value of ,4.5
(Figure 1, Panel A). This HRM region and cutoff value were
identified in a previous optimization study that evaluated MAAs
that included the HRM diversity assay, the BED-CEIA, the
BioRad-Avidity assay, and viral load [13]. The second new MAA
described in this report includes sequence ambiguity analysis as the
fourth assay, using an ambiguity cutoff value of ,0.5% (Figure 1,
Panel B). This cutoff value was used in a previous report that
evaluated the use of sequence ambiguity alone for identification of
recent HIV infections [3].
The two MAAs were evaluated using 1,782 samples from 709
individuals who enrolled in three cohort studies (MACS, ALIVE,
and HIVNET 001/001.1; see Methods). The mean window
HIV Diversity for Incidence Estimation
PLOS ONE | www.plosone.org 3 June 2014 | Volume 9 | Issue 6 | e101043period and shadow obtained for each MAA are shown in Figure 1.
The MAA that included the HRM diversity assay had a mean
window period of 141 days (95% CI: 113–168 days). The MAA
that included sequence ambiguity had a mean window period of
131 days (95% CI: 103–156 days). Additional statistical evaluation
of the two MAAs indicated that missing HRM data (for 8 samples)
and missing sequence ambiguity data (for 11 samples) did not have
a significant impact on the mean window periods determined for
the MAAs (data not shown). These analyses did suggest that results
generated using the MAA that includes the HRM diversity assay
are more stable in the presence of missing data (data not shown).
In a secondary analysis that accounted for missing data, the upper
boundary of the 95% confidence interval for the shadow of the
sequence ambiguity-based MAA was 456 days, indicating that this
MAA may be evaluating incidence in a time period that extends
more than 1 year before sample collection.
Models for the probability of MAA positive classification as a
function of duration of infection were generated for each of the
two MAAs (Figure 2). For comparison, the figure also includes a
model for the probability of assay positive classification using the
LAg-Avidity assay alone (cutoff,1.5 OD-n) [10]. For both MAAs,
the probability that samples were classified as MAA positive
approached zero with increasing duration of infection (i.e., all
individuals were eventually classified as MAA negative). This was
not the case when the LAg-Avidity assay was used alone. For the
MAAs, none of the 500 samples from individuals who were
infected more than 8 years (samples from the JHHCC) were
classified as MAA positive. In contrast, when the LAg-Avidity
assay was used alone, 29 [5.8%] of the 500 samples were
misclassified as assay positive [9,10].
The two MAAs were also used to estimate HIV incidence in
three clinical cohorts (HPTN 064, HIVNET 001/001.1, and
HPTN 064; see Methods, Table 1). The number of samples tested
in each step of the MAA, and the number of samples that met the
criteria for each assay, are shown in Table 1. The number of
serologic assays required for this type of assessment is influenced
by the assay order. If the BioRad-Avidity assay is performed first
(as shown in Figure 1 and Table 1), 301 (84%) of the 358 cohort
samples are identified as MAA negative in the first step of the
MAA, leaving 57 samples to be tested with the LAg-Avidity assay.
Overall, 415 serologic assays are required. In contrast, if the LAg-
Avidity assay is used as the first step in the MAA, only 270 (75%)
of the 358 cohort samples are identified as MAA negative, leaving
88 samples to be tested with the BioRad-Avidity assay. Overall,
Figure 1. Multi-assay algorithms (MAAs) for cross-sectional HIV incidence estimation. Two MAAs are shown. The mean window period
and shadow for each MAA are shown; 95% confidence intervals are shown in parentheses. Results from the component assays were expressed as
follows: BioRad-Avidity assay: percentage (avidity index); limiting antigen avidity enzyme immunoassay (LAg-Avidity): normalized optical density units
(OD-n); viral load: copies/mL; high resolution melting (HRM) diversity assay: single number (HRM score); sequence ambiguity: percentage.
doi:10.1371/journal.pone.0101043.g001
Figure 2. Proportion of samples classified as MAA positive as a
function of the duration of HIV infection. Probability curves are
shown for the two MAAs described in Figure 1. A probability curve is
also shown for the limiting antigen avidity assay (LAg-Avidity assay
cutoff,1.5 OD-n) alone [10]. Key: blue line, MAA with the high
resolution melting (HRM) diversity assay; green line, MAA with
sequence ambiguity; dotted line, LAg-Avidity assay alone.
doi:10.1371/journal.pone.0101043.g002
HIV Diversity for Incidence Estimation
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e101043446 serologic assays would be required. The MAAs are also
designed so that the more labor intensive and costly assays are
performed last. For HPTN 064, HIVNET 001/001.1, and HPTN
061, diversity assays were only required for 2, 16, and 13 samples,
respectively. For HIVNET 001/001.1, 1 of 16 samples was
identified as MAA negative by sequence ambiguity. For HPTN
061, 4 of 13 samples were identified as MAA negative by the
HRM diversity assay, and 3 of those 4 samples were identified as
MAA negative with sequence ambiguity (one sample failed
sequence analysis).
The cross-sectional incidence estimates obtained using the two
new MAAs are shown in Table 2. These estimates were nearly
identical to incidence estimates based on longitudinal cohort
follow-up (Table 2) [28,32,33]. For each cohort, the point
estimates of incidence obtained with the MAAs were within the
95% confidence intervals of the corresponding longitudinal
incidence estimates, further supporting the accuracy of the new
MAAs. All six of the MAA-derived incidence estimates differed by
,21% from the corresponding longitudinal incidence estimates
(percent difference, Table 2).
As a final step, we evaluated how inclusion of the diversity
measure (HRM score or sequence ambiguity) impacted the
performance of the MAAs. If the diversity measure was simply
removed from the MAA (leaving a non-optimized 3-assay MAA
with the same cutoffs for the other three assays), the proportion of
samples classified as MAA positive still approached zero (all of the
samples from individuals infected .8 years were classified as MAA
negative). However, some samples from individuals with long-term
infection (4–8 years) were classified as MAA positive (data not
shown). This is reflected in the longer mean window period (175
days) and longer shadow (411 days) of the non-optimized 3-assay
MAA compared to the two MAAs that include a diversity
measure. The shadow for this MAA means that incidence is being
assessed more than a year before sample collection, which does not
meet our pre-specified requirements for MAA performance. We
also compared the two new MAAs to an optimized 2-assay MAA
includes the BioRad-Avidity assay (cutoff,40%) and the LAg-
Avidity assay (cutoff,2.5 OD-n) [10]. The performance of this
MAA was not significantly impacted by the addition of viral load
[10]. As shown in Table 2, the 2-assay MAA has a shorter mean
window period than the two new MAAs (only 119 days; 95% CI:
94, 144) and a longer shadow (247 days, 95% CI: 160, 339 days).
The incidence estimates for the 2-assay MAA differed from the
longitudinal incidence estimates slightly more than the two new
MAAs. Furthermore, the shorter mean window period of the
optimized 2-assay MAA means that surveys would require larger
sample sizes to achieve the same level of precision in incidence
estimates as those obtained using the two new MAAs (see Table 2,
Relative survey size).
Discussion
This report demonstrates that HIV diversity is a useful
biomarker for cross-sectional HIV incidence estimation when
Table 1. Sample sizes used in calculating HIV incidence estimates for three clinical cohorts in the United States with two 4-assay
MAAs.
HPTN 064 HIVNET 001 HPTN 061
Length of follow-up (months)
a 6o r1 2
b 18 12
# HIV negative 1,947 4,175 872
# HIV positive
c 33 79
d 246
Assays/Test results
1. BioRad-Avidity assay # evaluated 33 79 246
# ,85% 3 24 30
2. LAg-Avidity assay # evaluated 3 24 30
# ,2.9 OD-n 3 20 24
3. Viral load # evaluated 3 20 24
# .400 copies/mL 2 16 13
4. HRM diversity assay # evaluated 2 16 13
# ,4.5 (# MAA positive) 21 6
e 9
f
4. Sequence ambiguity # evaluated 2 16 12
g
# ,0.5 (# MAA positive) 21 5
e 9
f
Abbreviations: HPTN: HIV Prevention Trials Network; HIVNET: HIV Network for Prevention Trials; MAA: multi-assay algorithm; LAg-Avidity: limited antigen avidity assay;
BioRad-Avidity: avidity assay based on the BioRad 1/2+O EIA; HRM: high resolution melting.
aCross-sectional HIV incidence estimates were obtained by testing samples collected at the end of follow-up in three clinical cohorts: HPTN 064, HIVNET 001, and HPTN
061. The number of HIV-infected vs. HIV-uninfected individuals included in the cross-sectional survey is shown.
bParticipants in HPTN 064 were followed for either 6 or 12 months.
cFor HPTN 064, 33 study participants had samples available for analysis; 28 were seropositive at enrollment, one had acute HIV infection at enrollment, and four
acquired HIV infection during the study. For HIVNET 001, 79 of 90 HIV-infected study participants had samples available for analysis; all 79 participants were HIV-
uninfected at study enrollment. For HPTN 061, 246 participants had samples available for analysis; 218 were seropositive at study enrollment, three had acute HIV
infection at enrollment, and 25 acquired HIV infection during the study.
d73 of these 79 samples were among the 808 samples from HIVNET 001 that were used to determine the window periods and shadows for the MAAs (see Figures 1 and
2).
eOne specimen classed as MAA positive by the HRM-based MAA was classified as MAA negative by the ambiguity-based MAA.
fOne specimen that was classified as MAA negative by the HRM-based MAA was classified as MAA positive by the ambiguity-based MAA.
gOne specimen failed analysis with sequence ambiguity. Because the MAA could not be completed, this specimen was excluded from incidence calculations.
doi:10.1371/journal.pone.0101043.t001
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estimates generated for three clinical cohorts using the two MAAs
described in this report were nearly identical to point estimates of
HIV incidence based on longitudinal follow-up. An advantage of
these MAAs is that they do not include CD4 cell count data, which
may be difficult to obtain in cross-sectional surveys. Therefore,
these MAAs allow the entire incidence assessment to be conducted
using stored plasma or serum samples.
In these MAAs, a hierarchical approach is used for testing.
Serologic assays, which are less costly and easier to perform, are
performed first, followed by HIV viral load. HIV diversity
assessments are required only for the small subset of samples with
results that fall below the assay cutoffs for the two serologic assays
and above the cutoff for HIV viral load. The cutoffs used for the
serologic assays (optimized in a previous MAA [10]) are higher
than the cutoffs recommended when the LAg-Avidity and BioRad-
Avidity assays are used in a single-assay format for HIV incidence
estimation. In those cases, assay cutoffs are selected to balance
detection of incident infections with exclusion of long-term
infections. In contrast, in the MAAs presented in this report,
higher cutoffs are used for the serologic assays to maximize
detection of incident infections. Specificity is achieved by using the
two serologic assays in combination, by excluding samples with
low viral load, and by excluding samples with high diversity. The
order in which the two serologic assays are performed impacts the
cost of incidence estimation using these MAAs. Because the
BioRad-Avidity assay identifies a higher proportion of the test
samples as MAA negative than the LAg-Avidity assay (using
cutoffs of ,85% and ,2.9 OD-n, respectively), fewer serologic
assays may be required when the BioRad-Avidity assay is
performed first.
In the MAAs described in this report, samples with viral loads ,
400 copies/mL are classified as MAA negative. Viral suppression
is associated with misclassification by the LAg-Avidity assay [34]
but has not been associated with misclassification using the
BioRad-Avidity assay [35]. Inclusion of viral load in the MAAs is
also helpful, since samples with very low HIV RNA levels are not
likely to be evaluable using the HRM diversity assay or sequence-
based assays, which require a minimal level of HIV RNA for
reverse transcription and PCR amplification (RT/PCR). In
samples that are amplifiable, one should also consider that low
viral load may impact diversity measures due to bottlenecking if
very few HIV RNA copies are used for RT/PCR. A previous
study demonstrated that the HRM diversity assay is only affected
by viral load if the number of copies of HIV RNA used for HRM
analysis is very low (e.g., ,50 copies input HIV RNA,
corresponding to a viral load of ,500 copies/mL for the methods
used in this report) [17]. Therefore, low viral load is not likely to
Table 2. Performance characteristics of MAAs and comparison of cross-sectional incidence estimates to longitudinal incidence
estimates obtained for three clinical cohorts.
Longitudinal cohort HRM-based MAA Sequence ambiguity-based MAA
2-assay MAA (no diversity
measure)*
Method description Gold standard
a This report This report Previous report
Mean window period – 141 (113, 168) 131 (103, 156) 119 (94, 144)
Shadow – 177 (132, 250) 172 (122, 251) 247 (160, 339)
Incidence estimate
HPTN 064 0.24% (0.07, 0.62) 0.27% (0.03, 0.98) 0.29% (0.03, 1.07) 0.32% (0.04, 1.17)
HIVNET 001 1.04% (0.70, 1.55) 1.13% (0.63, 1.93) 1.14% (0.62, 1.98) 0.92% (0.45, 1.73)
HPTN 061 3.02% (2.01, 4.37) 2.67% (1.20, 5.28) 2.88% (1.29, 5.70) 4.57% (2.37, 8.24)
Percent difference
b
HPTN 064 – 12.50% 20.83% 33.33%
HIVNET 001 – 8.65% 9.62% 11.54%
HPTN 061 – 11.59% 4.64% 51.32%
Relative survey size
c 0.84 0.91 1.00 (Reference)
*Includes only LAg-Avidity and BioRad avidity assays; addition of viral load did not impact MAA performance.
Abbreviations: HRM: high resolution melting; MAA: multi-assay algorithm; HPTN: HIV Prevention Trials Network; HIVNET: HIV Network for Prevention Trials.
The table compares performance characteristics of the HRM-based MAA (Figure 1), the sequence-ambiguity-based MAA (Figure 1), and a 2-assay MAA described in a
previous report [10]. The 2-assay MAA includes the LAg-Avidity assay (cutoff,2.8 OD-n) and the BioRad-Avidity assay (cutoff,40%); addition of HIV viral load to this
MAA did not improve assay performance [10]. For each MAA, the table shows the mean window period, the shadow, and the cross-sectional incidence estimates
obtained for each cohort. Methods used to calculate cross-sectional incidence estimates and confidence intervals have been described previously [13]. For each
incidence estimate, data presented include the point estimate of incidence (bolded) and the 95% confidence intervals for the incidence estimate (parentheses).
aLongitudinal incidence estimates were obtained previously for the three cohorts, where longitudinal HIV incidence=(number of seroconversion events)/(number of
person-years of follow-up) [28,32,33]. For HPTN 064 (low incidence cohort), longitudinal incidence was assessed over 6–12 months of follow-up (1,639 person/years);
four seroconverters were identified. For HIVNET 001 (medium incidence cohort), longitudinal incidence was assessed between the 12- and 18-month follow-up visits
(2,304 person years); 24 seroconverters were identified. For HPTN 061 (high incidence cohort), longitudinal incidence was assessed over 12 months of follow-up (926
person years); 28 seroconverters were identified.
bThe cross-sectional incidence estimates obtained for each MAA were compared to the longitudinal incidence estimates. The percent difference was calculated by the
following equation: [(absolute value of the cross-sectional incidence estimate minus the longitudinal incidence estimate)6(100)]/(the longitudinal incidence estimate).
cThe relative survey size shows the size of a cross-sectional survey that would be needed for each of the two new MAAs to obtain the same precision that would be
achieved using the previously optimized 2-assay MAA. Because both numbers are ,1, a smaller survey would be needed using either of the two new MAAs.
doi:10.1371/journal.pone.0101043.t002
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HIV diversity can also be impacted by clinical and biologic factors.
For example, genetic bottlenecking can occur in vivo in individuals
with advanced HIV disease [7,8,16] and in individuals with
prolonged exposure to a non-suppressive antiretroviral drug
regimen [36]. Higher levels of HIV diversity may also be observed
early in infection if the multiplicity of infection is high (e.g., in
persons who inject drugs) [37] or in cases of dual subtype HIV
infection [38]. These factors should be considered when HIV
diversity is used to assess HIV incidence.
In this study, similar performance was observed for the MAA
that includes the HRM diversity assay and the MAA that includes
sequence ambiguity. The characteristics of these two laboratory
methods are shown in Table S2. Several factors should be
considered when choosing an HIV diversity assay for inclusion in a
MAA. The HRM diversity assay is easier, faster, and less costly to
perform than HIV sequencing. Software has been developed that
automates calculation of single numeric HRM scores from melting
curve data, reducing the effort and variability associated with
manual HRM score calculation [29]. In contrast, the use of
sequencing data to quantify HIV diversity requires more complex
sample and data analysis protocols. The HRM diversity assay uses
the LightScanner instrument, which provides high resolution
melting curves with a high degree of temperature stability. While
DNA melting curve data can be obtained using other instruments
(e.g., those designed for real-time PCR), those instruments
typically provide lower resolution data and greater temperature
variability [39], and data from those instruments have not been
evaluated in MAAs for incidence determination. An advantage of
using sequence ambiguity to quantify HIV diversity is that many
laboratories perform HIV genotyping for resistance testing. The
HIV genotyping system used in this report (the ViroSeq HIV-1
Genotyping System) is commercially available and is used in many
laboratories in the US and elsewhere. In addition to providing
information on antiretroviral drug resistance, sequences generated
using the ViroSeq system can be used for phylogenetic analysis of
HIV in the MAA-positive samples.
Regardless of the method use to quantify viral diversity for HIV
incidence estimation, it is important to note that the level of
genetic diversity varies considerably in different regions of the HIV
genome [40]. The sequence ambiguity-based MAA described in
this report uses sequence ambiguity measures from a defined
portion of the HIV pol region. This region was selected for
convenience since pol data from this region are generated when the
ViroSeq HIV-1 Genotyping System is used for HIV resistance
testing. The region used for analysis with the HRM diversity assay
(ENV1) was selected in a previous study that compared the
performance of eight different regions for inclusion in MAAs for
HIV incidence estimation [13]. Performance of MAAs that
include sequence ambiguity is likely to be different than the
MAA described in this report if a different region were analyzed
(e.g., a different portion of the pol gene or another gene).
The sequence ambiguity measure used in the MAA in this
report is based on the percentage of mixed base positions detected
in a consensus sequence derived from population sequencing.
Detection of mixed base positions is impacted by numerous
factors, including the methods and platform used for sequence
analysis [41,42]. Detection of mixed bases is also impacted by the
amount of HIV RNA used for analysis and the efficiency of the
reverse transcription and amplification steps used to generate
amplicons for sequencing. Furthermore, even when the same
platform and methods are used to generate consensus sequences
(e.g., the ViroSeq HIV-1 Genotyping System used in this report),
the percentage of mixed base positions detected may be impacted
by variation in manual sequence editing, which involves subjective
interpretation of electropherogram data. Different users may
employ different approaches for sequence editing, and results may
vary from user to user [41]. Quality control measures are required
to minimize variation in HIV sequence data analysis that could
impact sequence ambiguity measures [43,44]. Increased cost and
labor and more complex data management protocols would be
required if next generation sequencing were used to generate
diversity measures for cross-sectional incidence studies. Regardless
of the method used to obtain diversity measures for cross-sectional
incidence analysis, strict quality control is needed to ensure the
reproducibility of the data. Furthermore, if the methods used to
quantify HIV diversity are different from those used in this report
(e.g., different genomic region, different sequencing platform, or
alternate sequencing approach) the assay or MAA would need to
be validated using large sample sets, similar to the approach used
in this report.
Both the HRM diversity assay and the sequence ambiguity
assay use DNA primers for reverse transcription and PCR. The
ViroSeq system also uses DNA primers for HIV sequencing. The
HRM diversity assay has been used successfully for analysis of
subtype A, B, C, and D HIV with relatively few assay failures [14],
and the ViroSeq system performs well across a wide range of HIV
subtypes [45]. In this report, which was based on analysis of
subtype B HIV, very few samples failed analysis with either assay.
This study only included samples from the US, which are likely
to be from individuals with subtype B infection. Further studies are
needed to evaluate the performance of HIV diversity-based MAAs
in populations infected with other HIV subtypes since serologic
assays may perform differently in some subtypes [46,47,48].
Additionally, the majority of the samples in this study were from
MSM. The viral populations in MSM may differ from those in
individuals infected through heterosexual contact or injection drug
use [37,49], impacting HIV diversity measures. It is noteworthy
that a previous study demonstrated that HRM scores were similar
in a US cohort (subtype B, MSM) and a cohort from Malawi
(subtype C, women), suggesting that HRM score results may not
be substantially impacted by differences in mode of infection,
subtype, or gender [16].
In summary, this report describes novel MAAs for cross-
sectional HIV incidence estimation in US populations. Future
studies will explore the use of HIV diversity-based MAAs for
analysis of HIV incidence in populations with other HIV subtypes.
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